{"id":"NCT00712933","sponsor":"Human Genome Sciences Inc., a GSK Company","briefTitle":"A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057","officialTitle":"A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™)a Fully Human Monoclonal Anti-BLyS Antibody in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05-30","primaryCompletion":"2016-12-09","completion":"2016-12-09","firstPosted":"2008-07-10","resultsPosted":"2018-01-16","lastUpdate":"2019-12-05"},"enrollment":738,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Systemic Lupus Erythematosus"],"interventions":[{"type":"DRUG","name":"belimumab","otherNames":["LymphoStat-B™","HGS1006"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2.","type":"EXPERIMENTAL"}],"summary":"This is a long-term continuation study to provide continuing treatment to subjects with SLE.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AE)","timeFrame":"Up to 9 years","effectByArm":[{"arm":"Belimumab 10mg/kg IV","deltaMin":706,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":110,"countries":["Argentina","Austria","Belgium","Brazil","Canada","Chile","Colombia","Czechia","France","Germany","Hong Kong","India","Israel","Italy","Mexico","Netherlands","Peru","Philippines","Poland","Puerto Rico","Romania","Russia","Slovakia","South Korea","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["26936891","31302695","33051264"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":231,"n":735},"commonTop":["Headache","Nasopharyngitis","Diarrhoea","Arthralgia","Influenza"]}}